Armata Pharmaceuticals (NYSEMKT:ARMP), a clinical-stage biotech developing bacteriophage therapies for drug-resistant bacterial infections, released its second-quarter results on August 12, 2025. The company posted GAAP revenue of $2.2 million, beating analyst GAAP revenue estimates of $1.38 million, mostly due to grant and award funding led by the U.S. Department of Defense.

The period was defined by major clinical progress—positive Phase 1b/2a results for its AP-SA02 candidate—yet also by continued financial strain as Armata seeks new funding for future trials.

Source: Analyst estimates for the quarter provided by FactSet.

Continue reading

Source Fool.com